Drug Topics
FEBRUARY 26, 2024
Participants of a recent study who received automated text messaging and monitoring, as well as peer support and coaching, increased PrEP uptake from 11% to over 20%.
Pharmacy Times
FEBRUARY 26, 2024
“I’m better than I was before I had long COVID, and in so many ways,” said a patient in an interview with Pharmacy Times.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
FEBRUARY 26, 2024
The increasing use of antidepressants observed before and after the public health crisis suggests a concerning mental health trend, especially among females.
PharmaVoice
FEBRUARY 26, 2024
GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has previously failed in the past.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
FEBRUARY 26, 2024
Simlandi is the only biosimilar to Humira on the market that is high-concentration, citrate-free, and interchangeable.
STAT
FEBRUARY 26, 2024
LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead. The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
FEBRUARY 26, 2024
As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound , they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease. A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunctio
Pharmacy Times
FEBRUARY 26, 2024
Investigators continue to conduct regulated and controlled clinical trials to build compelling, high-quality evidence on their therapeutic potential.
STAT
FEBRUARY 26, 2024
After the recent nitrogen gas execution in Alabama of Kenneth Smith, state Attorney General Steve Marshall said that nitrogen gas “was intended to be — and has now proved to be — an effective and humane method of execution.” It is hard to imagine a statement so obviously disconnected from facts. Eyewitness accounts described Smith’s death as a harrowing experience of dry heaving, thrashing, straining against leather straps, seizures, and terror.
Pharmaceutical Technology
FEBRUARY 26, 2024
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
FEBRUARY 26, 2024
Investigators found genetic evidence that certain sleep behaviors can be risk factors for lifespan.
pharmaphorum
FEBRUARY 26, 2024
Digital health company Akili expands beyond the US as partner Shionogi files for approval for its ADHD digital therapeutic (DTx) in Japan
Pharmacy Times
FEBRUARY 26, 2024
The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.
STAT
FEBRUARY 26, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because — you know what we are going to say — that oh-so familiar routine of online meetings, endless calls and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So let us be optimistic and convince ourselves we can nudge it in a better direction with a cup of stimulation.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Store News
FEBRUARY 26, 2024
The FTC alleges that the largest supermarket merger in U.S. history will eliminate competition and raise grocery prices for millions of Americans, while harming tens of thousands of workers.
pharmaphorum
FEBRUARY 26, 2024
Sanofi gets a win for its oral BTK inhibitor rilzabrutinib in chronic hive disorder CSU, setting up a phase 3 programme as it chases after Novartis’ remibrutinib in this indication.
Drug Store News
FEBRUARY 26, 2024
Dollar General celebrated the grand opening of its 20,000th store at its DG Market location in Alice, Texas.
pharmaphorum
FEBRUARY 26, 2024
GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
FEBRUARY 26, 2024
The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.
STAT
FEBRUARY 26, 2024
R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private. Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.
Pharmacy Times
FEBRUARY 26, 2024
As of January 2024, Keytruda has been approved for 6 indications in NSCLC across the metastatic and earlier stages of the disease.
Fierce Pharma
FEBRUARY 26, 2024
Bristol Myers Squibb’s first drug substance facility outside the United States is now set to become the company’s inaugural sterile drug product (SDP) facility in Europe, thanks to a multi-million- | Bristol Myers Squibb’s first drug substance facility outside the United States is now set to become the company’s inaugural sterile drug product (SDP) facility in Europe, thanks to a multi-million-dollar expansion expected to add hundreds of new jobs in the coming years.
Drug Store News
FEBRUARY 26, 2024
Geologie, a gender-neutral skin care brand, is making its exclusive debut at more than 800 Target locations nationwide.
pharmaphorum
FEBRUARY 26, 2024
Boehringer Ingelheim and Zealand Pharma report stellar top-line results for GLP-1/glucagon agonist survodutide in liver disease MASH.
Drug Store News
FEBRUARY 26, 2024
The Firming Serum Stick features a retinol-based formula that glides on clear and is packaged in an easy-to-apply stick format, the brand said.
STAT
FEBRUARY 26, 2024
The Aztecs called it teonanácatl, or “flesh of the Gods.” Some who ate the intoxicating mushroom “saw themselves dying in a vision and wept,” according to an account by a 16th-century Franciscan friar. “Others saw themselves being eaten by a wild beast; others imagined that they were capturing prisoners in battle, that they were rich.
Pharmaceutical Technology
FEBRUARY 26, 2024
Merck's KEYTRUDA has received a positive opinion from the EMA CHMP for use in combination with chemotherapy for non-small cell lung cancer.
STAT
FEBRUARY 26, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at some renewed interest in a yesteryear biotech craze, news of an FDA flex, and a dive into the science of vaccinology.
PharmaVoice
FEBRUARY 26, 2024
Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.
Fierce Pharma
FEBRUARY 26, 2024
Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” | Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” Dubbed “Amgen Ohio,” the nearly 300,000-square-foot biomanufacturing plant in New Albany, Ohio, is set to employ 400 full-time employees and leverage the “latest innovation and technology.
European Pharmaceutical Review
FEBRUARY 26, 2024
[The Phase II trial showed that] up to 83.0 percent of adults given survodutide (BI 456906) achieved a statistically significant improvement of the liver disease metabolic dysfunction-associated steatohepatitis (MASH)” Up to 83.0 percent of adults given survodutide (BI 456906) achieved a statistically significant improvement of the liver disease metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2 percent) in a Phase II trial.
Fierce Pharma
FEBRUARY 26, 2024
Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million. Now, the company is looking toward bringing the drug to Europe and Japan and testing a new eye-drop formulation.
Pharmaceutical Technology
FEBRUARY 26, 2024
SK bioscience has achieved a significant milestone with its typhoid conjugate vaccine, SKYTyphoid, receiving WHO prequalification.
Expert insights. Personalized for you.
407 
Let's personalize your content